Activation of the RON receptor tyrosine kinase attenuates transforming growth factor-beta1-induced apoptotic death and promotes phenotypic changes in mouse intestinal epithelial cells

Carcinogenesis. 2005 Jan;26(1):27-36. doi: 10.1093/carcin/bgh284. Epub 2004 Sep 24.

Abstract

The RON (recepteur d'origine nantais) receptor belongs to the MET proto-oncogene family that is implicated in the oncogenesis of the gastrointestinal epithelium. The present study aimed to determine the role of RON in regulating epithelial phenotypes in response to transforming growth factor (TGF)-beta1. Expression and activation of RON in SV40-immortalized mouse intestinal epithelial MODE-K cells result in reduction of cellular sensitivities towards apoptotic signals elicited by TGF-beta1. This effect is dependent on RON expression and phosphorylation that inhibit the TGF-beta1-induced activation of caspase-3 and truncation of BAD. Among cellular signaling components, the activation of MAP kinase is critical in the RON-mediated inhibitory effect. PD98059, a specific MAP kinase inhibitor, prevented RON-mediated anti-apoptotic activities. PD98059 also prevented the inhibitory effect of RON on TGF-beta1-induced cleavage of caspase-3 and BAD. By protecting cells from apoptotic death, activated RON collaborates with TGF-beta1 in the induction of cell morphological changes with decreased E-cadherin expression and increased migration and morphogenesis. Thus, RON expression and activation modulate phenotypes of gastrointestinal epithelial cells in response to TGF-beta1 with reduced sensitivity to apoptosis and increased migration. These activities might represent a mechanism by which RON activation increases tumorigenic activities and facilitates the progression of transformed epithelial cells towards malignancy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Apoptosis / physiology*
  • Blotting, Western
  • Cadherins / metabolism
  • Carrier Proteins / drug effects
  • Carrier Proteins / metabolism
  • Caspase 3
  • Caspases / drug effects
  • Caspases / metabolism
  • Cell Line
  • Enzyme Activation / drug effects
  • Enzyme Activation / physiology
  • Hepatocyte Growth Factor / pharmacology
  • Humans
  • Immunoprecipitation
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / physiology*
  • Intracellular Signaling Peptides and Proteins / pharmacology
  • Mice
  • Mitogen-Activated Protein Kinases / drug effects
  • Mitogen-Activated Protein Kinases / metabolism
  • Phenotype
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins / pharmacology
  • Receptor Protein-Tyrosine Kinases / metabolism*
  • Transforming Growth Factor beta / metabolism
  • Transforming Growth Factor beta / pharmacology*
  • Transforming Growth Factor beta1
  • bcl-Associated Death Protein

Substances

  • BAD protein, human
  • Bad protein, mouse
  • Cadherins
  • Carrier Proteins
  • Intracellular Signaling Peptides and Proteins
  • MAS1 protein, human
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins
  • TGFB1 protein, human
  • Tgfb1 protein, mouse
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1
  • bcl-Associated Death Protein
  • macrophage stimulating protein
  • protein kinase modulator
  • Hepatocyte Growth Factor
  • RON protein
  • Receptor Protein-Tyrosine Kinases
  • Mitogen-Activated Protein Kinases
  • CASP3 protein, human
  • Casp3 protein, mouse
  • Caspase 3
  • Caspases